ProMIS Neurosciences Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
PMN$4.05-2.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Shareholders’ Equity
Condensed Consolidated Statements of Changes in Shareholders’ Deficit
| | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · · · · · · Accumulated · · · · · · | ||||||||||||||||||||||
| · · Series 2 Convertible · · · · · · · Additional · · Other · · · · · | ||||||||||||||||||||||
| · · Preferred Shares · · Common Shares · · Paid-in · · Comprehensive · · Accumulated · · | ||||||||||||||||||||||
| · · Shares · · Amount · · Shares · · Amount · · Capital · · Loss · · Deficit · · Total | ||||||||||||||||||||||
| Balance, July 1, 2024 | 1,166,667 | $— | 18,961,116 | $— | $97,818,797 | $(371,184) | $(99,724,691) | $(2,277,078) | ||||||||||||||
| Share-based compensation expense | | — | | — | — | | — | | 121,036 | | — | | — | | | 121,036 | ||||||
| Conversion of Series 2 Convertible Preferred Shares | | (1,166,667) | | | — | | 1,166,667 | | | — | | | — | | | — | | | — | | | — |
| Issuance of Common Shares from exercise of pre-funded warrants | | — | | | — | | 2,803,738 | | | — | | | 28,039 | | | — | | | — | | | 28,039 |
| Issuance of Common Shares, pre-funded warrants and accompanying Common Share warrants in July 26, 2024 PIPE, net of issuance costs | | — | | | — | | 9,757,669 | | | — | | | — | | | — | | | — | | | — |
| Re-measurement of liability-classified CAD stock options as of September 30, 2024 | | — | | — | — | | — | | 125,398 | | — | | — | | | 125,398 | ||||||
| Net income | | — | | — | — | | — | | — | | — | | 9,275,825 | | | 9,275,825 | ||||||
| Balance, September 30, 2024 | — | | $— | | 32,689,190 | | $— | $98,093,270 | $(371,184) | $(90,448,866) | | $7,273,220 | ||||||||||
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · Accumulated · · · · · · | |||||||||||||||||
| · · · · · · · Additional · · Other · · · · · · | |||||||||||||||||
| · · Common Shares · · Paid-in · · Comprehensive · · Accumulated · · · | |||||||||||||||||
| · · Shares · · Amount · · Capital · · Loss · · Deficit · · Total | |||||||||||||||||
| Balance, July 1, 2025 | 32,689,190 | | $— | | $108,140,611 | | $(371,184) | | $(108,152,006) | | $(382,579) | ||||||
| Share-based compensation expense | | — | | — | | 197,147 | | | — | | | — | | | 197,147 | ||
| Issuance of Common Shares from ATM Offering, net of issuance costs | | 1,019,877 | | — | | 708,468 | | | — | | | — | | | 708,468 | ||
| Issuance of pre-funded warrants from July 2025 Registered Direct Offering, net of issuance costs | | — | | | — | | | 697,658 | | | — | | | — | | | 697,658 |
| Issuance of Common Shares from exercise of pre-funded warrants | | 1,279,923 | | — | | 3,050 | | | — | | | — | | | 3,050 | ||
| Proceeds from issuance of Common Shares and warrants from July 22, 2025 discounted warrant exercise and PIPE, net of issuance costs | | 8,411,213 | | — | | 8,391,027 | | | — | | | — | | | 8,391,027 | ||
| Proceeds from issuance of Common Shares and warrants from July 28, 2025 discounted warrant exercise and PIPE, net of issuance costs | | 10,410,907 | | — | | 11,144,468 | | | — | | | — | | | 11,144,468 | ||
| Re-measurement of liability-classified CAD stock options as of September 30, 2025 | | — | | — | | | 8,242 | | | — | | | — | | | 8,242 | |
| Net loss | — | | — | | — | | — | | (11,580,126) | | (11,580,126) | ||||||
| Balance, September 30, 2025 | 53,811,110 | | $— | | $129,290,671 | | $(371,184) | | $(119,732,132) | | $9,187,355 | ||||||
| | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · · · · · · Accumulated · · · · · · | ||||||||||||||||||||||
| · · Series 2 Convertible · · · · · · · Additional · · Other · · · · · | ||||||||||||||||||||||
| · · Preferred Shares · · Common Shares · · Paid-in · · Comprehensive · · Accumulated · · | ||||||||||||||||||||||
| · · Shares · · Amount · · Shares · · Amount · · Capital · · Loss · · Deficit · · Total | ||||||||||||||||||||||
| Balance, January 1, 2024 | 1,166,667 | $— | 18,885,254 | | $— | $97,590,426 | $(371,184) | $(93,465,946) | $3,753,296 | |||||||||||||
| Share-based compensation expense | — | | — | — | | — | | 202,619 | | — | | — | | | 202,619 | |||||||
| Conversion of Series 2 Convertible Preferred Shares | | (1,166,667) | | | — | | 1,166,667 | | | — | | | — | | | — | | | — | | | — |
| Issuance of Common Shares from ATM Offering, net of issuance costs | | — | | — | 75,862 | | — | | 190,274 | | — | | — | | | 190,274 | ||||||
| Issuance of Common Shares from exercise of pre-funded warrants | | — | | | — | | 2,803,738 | | | — | | | 28,039 | | | — | | | — | | | 28,039 |
| Issuance of Common Shares, pre-funded warrants and accompanying Common Share warrants in July 26, 2024 PIPE, net of issuance costs | | — | | | — | | 9,757,669 | | | — | | | — | | | — | | | — | | | — |
| Re-measurement of liability-classified CAD stock options as of June 30, 2024 | | — | | — | — | | — | | | 81,912 | | — | | — | | | 81,912 | |||||
| Net income | — | | | — | — | | — | | — | | — | | 3,017,080 | | | 3,017,080 | ||||||
| Balance, September 30, 2024 | — | | $— | | 32,689,190 | | $— | $98,093,270 | $(371,184) | $(90,448,866) | | $7,273,220 | ||||||||||
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · Accumulated · · · · · · | |||||||||||||||||
| · · · · · · · Additional · · Other · · · · · · | |||||||||||||||||
| · · Common Shares · · Paid-in · · Comprehensive · · Accumulated · · · | |||||||||||||||||
| · · Shares · · Amount · · Capital · · Loss · · Deficit · · Total | |||||||||||||||||
| Balance, January 1, 2025 | 32,689,190 | $— | $107,546,433 | $(371,184) | $(90,687,073) | $16,488,176 | |||||||||||
| Share-based compensation expense | — | | — | | 654,457 | | — | | — | | 654,457 | ||||||
| Issuance of Common Shares from ATM Offering, net of issuance costs | | 1,019,877 | | — | | 708,468 | | | — | | | — | | | 708,468 | ||
| Issuance of pre-funded warrants from July 2025 Registered Direct Offering, net of issuance costs | | — | | | — | | | 697,658 | | | — | | | — | | | 697,658 |
| Issuance of Common Shares from exercise of pre-funded warrants | | 1,279,923 | | — | | 3,050 | | | — | | | — | | | 3,050 | ||
| Proceeds from issuance of Common Shares and warrants from July 22, 2025 discounted warrant exercise and PIPE, net of issuance costs | | 8,411,213 | | — | | 8,391,027 | | | — | | | — | | | 8,391,027 | ||
| Proceeds from issuance of Common Shares and warrants from July 28, 2025 discounted warrant exercise and PIPE, net of issuance costs | | 10,410,907 | | — | | 11,144,468 | | | — | | | — | | | 11,144,468 | ||
| Re-measurement of liability-classified CAD stock options as of September 30, 2025 | | — | | — | | | 145,110 | | | — | | | — | | | 145,110 | |
| Net loss | — | | — | | — | | — | | (29,045,059) | | (29,045,059) | ||||||
| Balance, September 30, 2025 | 53,811,110 | | $— | | $129,290,671 | | $(371,184) | | $(119,732,132) | | $9,187,355 | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.